Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records
Abstract Background Cardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among pa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Journal of Diabetes |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1753-0407.13604 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846107419032158208 |
|---|---|
| author | Haowen Hsu Paul Thomas Kocis Ariana Pichardo‐Lowden Wenke Hwang |
| author_facet | Haowen Hsu Paul Thomas Kocis Ariana Pichardo‐Lowden Wenke Hwang |
| author_sort | Haowen Hsu |
| collection | DOAJ |
| description | Abstract Background Cardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among patients with T2DM, including Hemoglobin A1c variability score (HVS) and early use of MACE‐preventive glucose‐lowering medications (GLMs). Methods We conducted a longitudinal cohort study to retrospectively review electronic health records between 2011 and 2022. Patients with T2DM ≥18 years without previous stroke or acute myocardial infarction (AMI) were included. Cox regression was utilized to investigate MACE risk factors and compare MACE risk reduction associated with early use of MACE‐preventive GLMs. Results A total of 19 685 subjects were included, with 5431 having MACE, including 4453 strokes, 977 AMI, and 1 death. There were 11 123 subjects with good baseline GC. Subjects with good baseline GC had 0.837 (confidence interval [CI]: 0.782–0.895) times lower MACE risk than their counterpart. Subjects with a single MACE‐preventive GLM at baseline with continuous use >365 days showed a decreased MACE hazard ratio (0.681; CI: 0.635–0.731). Among all MACE‐preventive GLMs, semaglutide provided a more significant MACE‐preventive effect. Conclusions This study identified that GLM, early GC, and HVS are MACE determinants among patients with T2DM. Novel GLM, adequate GC, and reduction of HVS can benefit MACE outcomes. |
| format | Article |
| id | doaj-art-60d328d32a8443ffafb48ff63329b351 |
| institution | Kabale University |
| issn | 1753-0393 1753-0407 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes |
| spelling | doaj-art-60d328d32a8443ffafb48ff63329b3512024-12-26T11:52:04ZengWileyJournal of Diabetes1753-03931753-04072024-10-011610n/an/a10.1111/1753-0407.13604Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health recordsHaowen Hsu0Paul Thomas Kocis1Ariana Pichardo‐Lowden2Wenke Hwang3Department of Clinical Pharmacy School of Pharmacy, College of Pharmacy, Taipei Medical University Taipei TaiwanDepartment of Pharmacy Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania USADepartment of Medicine Penn State Health Milton S Hershey Medical Center Hershey Pennsylvania USADepartment of Public Health Sciences College of Medicine, Penn State University Hershey Pennsylvania USAAbstract Background Cardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among patients with T2DM, including Hemoglobin A1c variability score (HVS) and early use of MACE‐preventive glucose‐lowering medications (GLMs). Methods We conducted a longitudinal cohort study to retrospectively review electronic health records between 2011 and 2022. Patients with T2DM ≥18 years without previous stroke or acute myocardial infarction (AMI) were included. Cox regression was utilized to investigate MACE risk factors and compare MACE risk reduction associated with early use of MACE‐preventive GLMs. Results A total of 19 685 subjects were included, with 5431 having MACE, including 4453 strokes, 977 AMI, and 1 death. There were 11 123 subjects with good baseline GC. Subjects with good baseline GC had 0.837 (confidence interval [CI]: 0.782–0.895) times lower MACE risk than their counterpart. Subjects with a single MACE‐preventive GLM at baseline with continuous use >365 days showed a decreased MACE hazard ratio (0.681; CI: 0.635–0.731). Among all MACE‐preventive GLMs, semaglutide provided a more significant MACE‐preventive effect. Conclusions This study identified that GLM, early GC, and HVS are MACE determinants among patients with T2DM. Novel GLM, adequate GC, and reduction of HVS can benefit MACE outcomes.https://doi.org/10.1111/1753-0407.13604glucose‐lowering medicationsglycemic controlmajor adverse cardiovascular eventsprimary preventiontype 2 diabetes |
| spellingShingle | Haowen Hsu Paul Thomas Kocis Ariana Pichardo‐Lowden Wenke Hwang Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records Journal of Diabetes glucose‐lowering medications glycemic control major adverse cardiovascular events primary prevention type 2 diabetes |
| title | Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records |
| title_full | Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records |
| title_fullStr | Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records |
| title_full_unstemmed | Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records |
| title_short | Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records |
| title_sort | major adverse cardiovascular events reduction and their association with glucose lowering medications and glycemic control among patients with type 2 diabetes a retrospective cohort study using electronic health records |
| topic | glucose‐lowering medications glycemic control major adverse cardiovascular events primary prevention type 2 diabetes |
| url | https://doi.org/10.1111/1753-0407.13604 |
| work_keys_str_mv | AT haowenhsu majoradversecardiovasculareventsreductionandtheirassociationwithglucoseloweringmedicationsandglycemiccontrolamongpatientswithtype2diabetesaretrospectivecohortstudyusingelectronichealthrecords AT paulthomaskocis majoradversecardiovasculareventsreductionandtheirassociationwithglucoseloweringmedicationsandglycemiccontrolamongpatientswithtype2diabetesaretrospectivecohortstudyusingelectronichealthrecords AT arianapichardolowden majoradversecardiovasculareventsreductionandtheirassociationwithglucoseloweringmedicationsandglycemiccontrolamongpatientswithtype2diabetesaretrospectivecohortstudyusingelectronichealthrecords AT wenkehwang majoradversecardiovasculareventsreductionandtheirassociationwithglucoseloweringmedicationsandglycemiccontrolamongpatientswithtype2diabetesaretrospectivecohortstudyusingelectronichealthrecords |